key: cord-0915655-1som1cqw authors: Burton, Alice R.; Maini, Mala K. title: Human antiviral B cell responses: Emerging lessons from hepatitis B and COVID‐19 date: 2021-02-08 journal: Immunol Rev DOI: 10.1111/imr.12953 sha: 3422ba40dcb5491729808cdedbaacc1301dffac5 doc_id: 915655 cord_uid: 1som1cqw Humoral immunity is a critical component of the coordinated response required to resolve viral infections and mediate protection following pathogen clearance or vaccination. A better understanding of factors shaping the memory B cell response will allow tailored development of efficient preventative vaccines against emerging acute viral infections, therapeutic vaccines, and immunotherapies for chronic viral infections. Here, we use recent data obtained by profiling antigen‐specific B cell responses in hepatitis B as a framework to explore lessons that can be learnt from different viral infections about the diverse influences on humoral immunity. Hepatitis B provides a paradigm where successful B cell responses in resolved or vaccinated individuals can be contrasted to the failed response in chronic infection, while also exemplifying the degree to which B cell responses within infected individuals can differ to two antigens from the same virus. Drawing on studies in other human and murine infections, including emerging data from COVID‐19, we consider the influence of antigen quantity and structure on the quality of the B cell response, the role of differential CD4 help, the importance of germinal center vs extrafollicular responses and the emerging concept that responses residing in non‐lymphoid organs can participate in B cell memory. While the GC has remained the focus of B cell research, it has long been appreciated that antibody responses can also develop outside of the B cell follicle in the absence of notable GCs. Extrafollicular differentiation of naive B cells into short-lived antibody secreting cells has been shown to mediate early antiviral immune protection in mice, 1 with extrafollicular B cells also able to undergo affinity maturation and generate both memory and long-lived plasma cells independently of T cell help. [2] [3] [4] [5] These responses provide malleable first line defense against replicating pathogens, yet may also contribute to autoantibody production and immunopathology. Although the roles of B cells in viral infections are diverse and wide-ranging, including immunoregulatory cytokine production and antigen presentation, this review will concentrate on findings from new studies in hepatitis B, SARS-CoV-2 infection and other human and murine infections to consider emerging concepts regarding the factors that govern memory B cell differentiation and their impact on humoral immunity. Due to the role of virus surface proteins in facilitating virus entrance, antibodies targeting HBsAg have strong neutralizing activity, 7, 8 interfering with the attachment of the "a"-determinant region of the virus to heparan sulfate proteoglycans on hepatocytes, or blocking binding of the pre-S1 domain of HBsAg to the host cellular receptor, sodium taurocholate co-transporting polypeptide (NTCP). Therefore, a lack of neutralizing anti-HBs, in combination with weak and exhausted HBV-specific CD8 T cells, is thought to contribute to viral persistence in chronically infected patients 9,10 and remains an elusive goal of therapies aiming to achieve a functional cure. Clinically, CHB can be further divided into discrete phases of disease classified on the basis of ongoing viremia, liver inflammation, and HBsAg load, facilitating detailed analysis as to how fluctuations in these disease parameters can influence immunity. Thus, divergent humoral immune responses can be studied not only between HBV-vaccinated, resolved, or chronically infected individuals but also within patients with CHB, comparing responses to HBsAg and HBcAg and different phases of disease. It is increasingly recognized that chronic viral infections, such Understanding these factors may reveal key insights into how B cell immunity is established following viral infection and how these pathways may be disrupted in chronic infection. One key piece of evidence may reside in the observation that B cell depletion by anti-CD20 or anti-CD52 antibody therapies (eg, the use of Rituximab in the management of lymphoma) significantly increases the risk of HBV-reactivation in HBV-resolved patients and of viremic flares in chronically infected patients with low viral loads (HBsAg + inactive carriers). [11] [12] [13] Long-lived plasma cells lack expression of CD20 and so should be preserved following Rituximab treatment; as a key cell population responsible for providing long-term antibody production, these cells might be expected to maintain serum antibody responses in the absence of memory B cells. 14 The observation that Rituximab can lead to loss of humoral immunity in these settings therefore suggests that long-lived plasma cells may not be reliably What can be learned from the dichotomous response to the surface and core antigens in hepatitis B about the role of antigen load or specific antigen structure in regulating humoral responses? In line with their lack of detectable antibodies against HBsAg, patients with CHB are shown to have reduced numbers of functional HBsAg-specific responses by ELISpot compared to those with acute-resolving infection. [17] [18] [19] [20] [21] However, application of fluorescently labeled antigen-bait systems was able to reveal for the first time that HBsAg-specific B cells in fact persist at equivalent levels in patients with chronic or acute-resolving infection and HBV-vaccinated controls but are functionally defective, failing to produce detectable anti-HBs upon stimulation in vitro. 22, 23 Comparatively, HBcAg-specific B cells are present at much higher frequencies than HBsAg-specific B cells, 24 with their number associated with elevated liver inflammation and ongoing viral replication. 25 In stark contrast to HBsAg-specific B cells, HBcAg-specific B cells maintain an ability to secrete anti-HBc antibodies upon IL-2, IL-21 and CD40 stimulation. 24 These data therefore suggest that the absence of anti-HBs in patient sera is a result of defective HBsAg-specific B cells rather than a complete loss of this B cells with HBsAg-specificity. HBsAg-specific B cells, HBcAg-specific B cells were phenotypically dominated by IgG-switched CD27 + CD21 + classical memory B cells (cMBCs), 24 which persist long-term independently of antigen 30, 31 and retain the capacity to proliferate and differentiate upon secondary exposure faster than naive B cells. 32, 33 Hence, the comparative dominance of atMBCs and cMBCs in HBsAg-and HBcAg-specific responses respectively may explain the difference in the formation of productive and long-lived humoral responses. Antigen-experienced atMBCs have been described in many different infection settings and are thought to represent a distinct memory B cell population that diverges from cMBCs. 34 Their presence in these contexts may give some clues as to factors that perturb memory B cell responses in chronic infections (summarized in Figure 1 ). Accumulating evidence suggests that atMBCs arise following repeated antigen challenge in an inflammatory setting inferring that these cells are perpetuated by persistent antigenic stimulation 35 ; in support, the frequency of atMBCs observed in HIV infection falls in line with treatment-induced reductions in viral load [36] [37] [38] and in those that spontaneously resolve infection. 39, 40 Thus, the accumulation of these cells in CHB appears to be, at least in part, driven by chronic exposure to HBV-viral proteins, as evidenced by the higher frequency of atMBCs in patients with ongoing infection compared with vaccinated or resolved controls. In addition to secreting full replicating virions, HBV-infected hepatocytes also release vast quantities of subviral particles-or "empty" viruses comprised of HBsAg in various sizes. These subviral particles flood the system, outnumbering infectious virus by 1000-to 100 000-fold, 41 Humoral immunity may also be regulated via properties intrinsic to the antigen in question. A key differential between HBcAg-and HBsAg-specific responses is the ability of HBcAg to promote B cell differentiation and isotype switching independently of CD4 T cell help. 59 HBcAg is distinct from HBsAg in its capacity to self-assemble into highly immunogenic virus-like particles that can bind and activate naive B cells in a T cell-independent fashion. 60 helper cells in vivo. 61 Since GC formation and function are critically dependent on T FH cell function, defective humoral immunity is closely associated with im- ARB and MKM are funded by a WT Investigator award (101849/Z/13/A) and a NIHR EME grant. Sciences, F. Hoffmann-La Roche and Immunocore and has served as a consultant or on advisory boards for Gilead Sciences, F. Hoffmann-La Roche, Immunocore and GSK. MKM and ARB have filed IP on a method to enhance HBV-specific immune responses. Alice R. Burton https://orcid.org/0000-0003-1049-1176 Mala K. Maini https://orcid.org/0000-0001-6384-1462 B cell activation and response regulation during viral infections The continuing story of T-cell independent antibodies Salmonella infection drives promiscuous B cell activation followed by extrafollicular affinity maturation Long-lived antigeninduced IgM plasma cells demonstrate somatic mutations and contribute to long-term protection Splenic extrafollicular reactions and BM plasma cells sustain IgM response associated with hypercholesterolemia Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections A human monoclonal antibody against hepatitis B surface antigen with potent neutralizing activity Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus Adaptive immunity in HBV infection Restoring, releasing or replacing adaptive immunity in chronic hepatitis B B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies and future directions Immunosuppression and HBV reactivation Plasma cell survival in the absence of B cell memory Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers A combination of human broadly neutralizing antibodies against hepatitis B virus HBsAg with distinct epitopes suppresses escape mutations Immunoregulation of the in vitro anti-HBs antibody synthesis in chronic HBsAg carriers and in recently boosted anti-hepatitis B vaccine recipients Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers T-and B-cell responses and previous exposure to hepatitis B virus in 'anti-HBc alone' patients Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients Circulating and intrahepatic antiviral B cells are defective in hepatitis B PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV HBV induces inhibitory FcRL receptor on B cells and dysregulates B cell-T follicular helper cell axis Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia Complement receptor 2/CD21-human naive B cells contain mostly autoreactive unresponsive clones Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function Memory B-cell persistence is independent of persisting immunizing antigen Cutting edge: long-term B cell memory in humans after smallpox vaccination Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses T-bet+ memory B cells: generation, function, and fate Atypical memory B cells in human chronic infectious diseases: an interim report Emergence of exhausted B cells in asymptomatic HIV-1-infected patients naïve for HAART is related to reduced immune surveillance Frequency and phenotype of B cell subpopulations in young and aged HIV-1 infected patients receiving ART Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations Decoupling activation and exhaustion of B cells in spontaneous controllers of HIV infection Control of viremia enables acquisition of resting memory B cells with age and normalization of activated B cell phenotypes in HIV-infected children Properties of subviral particles of hepatitis B virus Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIVinfected viremic individuals Low CD21 expression defines a population of recent germinal center graduates primed for plasma cell differentiation Atypical B cells are a normal component of immune responses to vaccination and infection in humans. bioRxiv B cell profiling in malaria reveals expansion and remodeling of CD11c + B cell subsets CD11c expression identifies a population of extrafollicular antigen-specific splenic plasmablasts responsible for CD4 T-independent antibody responses during intracellular bacterial infection Plasmodiumspecific atypical memory B cells are short-lived activated B cells. eLife The transcription factor T-bet resolves memory B cell subsets with distinct tissue distributions and antibody specificities in mice and humans T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response Defining antigenspecific plasmablast and memory B cell subsets in human blood after viral infection or vaccination Fcrl5 and T-bet define influenza-specific memory B cells that predict long-lived antibody responses. bioRxiv Functional characterization of CD11c+ age-associated B cells as memory B cells FCRL5+ memory B cells exhibit robust recall responses Cutting edge: B cellintrinsic T-bet expression is required to control chronic viral infection Enhancing SIV-specific immunity in vivo by PD-1 blockade The enigma of concurrent hepatitis B surface antigen (HBsAg) and antibodies to HBsAg Fc|[gamma]| receptors as regulators of immune responses IgG3 regulates tissue-like memory B cells in HIV-infected individuals The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen Hepatitis B virus core antigen binds and activates naive human B cells in vivo: studies with a human PBL-NOD/SCID mouse model Role of B cells in antigen presentation of the hepatitis B core Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus Epigenetic programming underpins B cell dysfunction in human SLE Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19 Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19 Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19 Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Functional SARS-CoV-2-specific immune memory persists after mild COVID-19 Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome SARS-CoV-2 specific antibody rearrangements in pre-pandemic immune repertoires of risk cohorts and COVID-19 patients Antibody responses to SARS-CoV-2 in patients with COVID-19 Convergent antibody responses to SARS-CoV-2 in convalescent individuals Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID-19 patients with pneumonia Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications Human neutralizing antibodies elicited by SARS-CoV-2 infection Next-generation sequencing of the intrahepatic antibody repertoire delineates a unique B-cell response in HBV-associated acute liver failure Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure Chronic viral infection promotes efficient germinal center B cell responses Quantitative and qualitative analysis of humoral immunity reveals continued and personalized evolution in chronic viral infection Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients Persistent viral presence determines the clinical course of the disease in COVID-19 Altered memory circulating T follicular helper-B cell interaction in early acute HIV infection Early ART in acute HIV-1 infection: impact on the B-cell compartment Inhibitory phenotype of HBV-specific CD4+ T-cells is characterized by high PD-1 expression but absent coregulation of multiple inhibitory molecules An OX40/OX40L interaction directs successful immunity to hepatitis B virus Circulating regulatory Tfh cells are enriched in patients with chronic hepatitis B infection and induce the differentiation of regulatory B cells Dysregulated response of follicular helper T cells to hepatitis B surface antigen promotes HBV persistence in mice and associates with outcomes of patients Age-associated B cells express a diverse repertoire of VH and Vκ genes with somatic hypermutation Cutting edge: IL-4, IL-21, and IFN-γ interact to govern T-bet and CD11c expression in TLRactivated B cells Severe malaria infections impair germinal center responses by inhibiting T follicular helper cell differentiation Overexpression of Tbet in HIV infection is associated with accumulation of B cells outside germinal centers and poor affinity maturation Spatiotemporal regulation of type I interferon expression determines the antiviral polarization of CD4 + T cells CD11c+ T-bet+ B cells require IL-21 and IFN-γ from type 1 T follicular helper cells and intrinsic Bcl-6 expression but develop normally in the absence of T-bet CD11c-Expressing B Cells Are Located at the T Cell/B Cell Border in Spleen and Are Potent APCs Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells The establishment of resident memory B cells in the lung requires local antigen encounter Type I interferon induces CXCL13 to support ectopic germinal center formation Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs Distinct germinal center selection at local sites shapes memory B cell response to viral escape Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B Functional B-cell response in intrahepatic lymphoid follicles in chronic hepatitis C Intrahepatic B-cell follicles of chronically hepatitis C virus-infected individuals lack signs of an ectopic germinal center reaction Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells Memory B cells in the lung participate in protective humoral immune responses to pulmonary influenza virus reinfection The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus Human antiviral B cells responses: Emerging lessons from hepatitis B and COVID-19